Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.39 |
| ▸ | ADH1B | P00325 | 1/20 | 0.34 |
| ▸ | ADH1C | P00326 | 1/20 | 0.34 |
| ▸ | ADH1A | P07327 | 1/20 | 0.34 |
| ▸ | ADH4 | P08319 | 1/20 | 0.34 |
| ▸ | ADH7 | P40394 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | METAP1 | P53582 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2240667 | 0.97 | — | — | |
| SCHEMBL962972 | 0.92 | — | — | |
| SCHEMBL542372 | 0.86 | — | — | |
| SCHEMBL6589344 | 0.85 | CYP1A2 (0.50) | CYP1A2SIGMAR1ADH1BADH1CADH1A | |
| SCHEMBL450392 | 0.85 | CYP1A2 (0.50) | CYP1A2SIGMAR1ADH1BADH1CADH1A | |
| SCHEMBL452274 | 0.83 | SIGMAR1 (0.50) | CYP1A2SIGMAR1CHRM5ADRA2CEPHX1 | |
| SCHEMBL7403531 | 0.83 | SIGMAR1 (0.50) | CYP1A2SIGMAR1CHRM5ADRA2CEPHX1 | |
| SCHEMBL6033221 | 0.82 | CYP1A2 (0.46) | CYP1A2SIGMAR1CHRM5ADRA2CEPHX1 | |
| SCHEMBL6877800 | 0.78 | CYP1A2 (0.46) | CYP1A2SIGMAR1ADH1BADH1CADH1A | |
| SCHEMBL6593058 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 592 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1599464-B1 | NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS | AVENTIS PHARMA SA (FR) | 2010-09-22 | — | — | EP | claimed |
| US-20070249710-A1 | Biaromatic compounds and cosmetic/pharmaceutical applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-10-25 | — | — | US | claimed |
| US-20240199623-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS CFTR MODULATORS | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2024-06-20 | — | — | US | disclosed |
| US-20240166593-A1 | LIPIDS SUITABLE FOR NUCLEIC ACID DELIVERY | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2024-05-23 | — | — | US | disclosed |
| EP-4370106-A1 | CANNABIDIOLIC ACID ESTERS FOR TREATING PRADER-WILLI SYNDROME | EPM (IP), Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| US-11970493-B2 | Autotaxin inhibitor compounds | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2024-04-30 | — | — | US | disclosed |
| CN-117813081-A | Cannabidiol esters for the treatment of Prader-Willi syndrome | EPM(IP)公司 | 2024-04-02 | — | — | CN | disclosed |
| WO-2024003906-A1 | CANNABINOID DERIVATIVES AND COMPOSITIONS COMPRISING SAME | CANNASOUL ANALYTICS LTD. (IL) | 2024-01-04 | — | — | WO | disclosed |
| US-11851389-B2 | Cationic lipids for nucleic acid delivery and preparation thereof | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2023-12-26 | — | — | US | disclosed |
| WO-2023244059-A1 | METHODS OF TREATING CANCER USING DUAL ANDROGEN RECEPTOR AND PDE5 INHIBITOR COMPOUNDS | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-12-21 | — | — | WO | disclosed |
| EP-4288104-A1 | LIPIDS SUITABLE FOR NUCLEIC ACID DELIVERY | Ramot at Tel-Aviv University Ltd. (IL) | 2023-12-13 | — | — | EP | disclosed |
| WO-1998054158-A1 | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p56lck TYROSINE KINASES | RHÔNE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-12-03 | — | — | WO | disclosed |
| WO-1998054157-A1 | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR p561ck TYROSINE KINASES | RHÔNE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-12-03 | — | — | WO | disclosed |
| WO-1998051324-A1 | PEPTIDE PARATHYROID HORMONE ANALOGS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-11-19 | — | — | WO | disclosed |
| EP-0871439-A1 | SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1998-10-21 | — | — | EP | disclosed |
| WO-1998032734-A1 | SUBSTITUTED β-THIOCARBOXYLIC ACIDS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-07-30 | — | — | WO | disclosed |
| WO-1998029376-A1 | PROCESS FOR THE SOLID PHASE SYNTHESIS OF ALDEHYDES, KETONES, OXIMES, AMINES AND HYDROXAMIC ACID COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-07-09 | — | — | WO | disclosed |
| US-5750540-A | SIDE EFFECT REDUCTION | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1998-05-12 | — | — | US | disclosed |
| EP-0823423-A1 | 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1998-02-11 | — | — | EP | disclosed |
| WO-1997024117-A1 | SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11851389-B2 | Cationic lipids for nucleic acid delivery and preparation thereof | NPC1L1, NPC1, CETP | CYP1A2 4711/4885SIGMAR1 2111/4885ADH1B 2789/4885 |
| US-20240199623-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS CFTR MODULATORS | PDE4A, PDE4B, PDE6C | CYP1A2 2115/4885SIGMAR1 3875/4885ADH1B 1270/4885 |
| US-20240166593-A1 | LIPIDS SUITABLE FOR NUCLEIC ACID DELIVERY | NPC1L1, NPC1, FASN | CYP1A2 4572/4885SIGMAR1 2483/4885ADH1B 1694/4885 |
| US-11970493-B2 | Autotaxin inhibitor compounds | ENPP2, ATXN10, ATXN2L | CYP1A2 4674/4885SIGMAR1 4497/4885ADH1B 4688/4885 |
| US-20070249710-A1 | Biaromatic compounds and cosmetic/pharmaceutical applications thereof | RARG, RARA, RARB | CYP1A2 463/4885SIGMAR1 3668/4885ADH1B 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.